Recombinant multi-species NLRP3 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine NLRP3 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
This gene encodes a pyrin-like protein containing a pyrin domain, a nucleotide-binding site (NBS) domain, and a leucine-rich repeat (LRR) motif. This protein interacts with the apoptosis-associated speck-like protein PYCARD/ASC, which contains a caspase recruitment domain, and is a member of the NLRP3 inflammasome complex. This complex functions as an upstream activator of NF-kappaB signaling, and it plays a role in the regulation of inflammation, the immune response, and apoptosis. The SARS-CoV 3a protein, a transmembrane pore-forming viroporin, has been shown to activate the NLRP3 inflammasome via the formation of ion channels in macrophages. Mutations in this gene are associated with familial cold autoinflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS), chronic infantile neurological cutaneous and articular (CINCA) syndrome, neonatal-onset multisystem inflammatory disease (NOMID), keratoendotheliitis fugax hereditarian, and deafness, autosomal dominant 34, with or without inflammation. Multiple alternatively spliced transcript variants encoding distinct isoforms have been identified for this gene. Alternative 5' UTR structures are suggested by available data; however, insufficient evidence is available to determine if all of the represented 5' UTR splice patterns are biologically valid. [provided by RefSeq, Aug 2020]
The Alternative Names of target: AGTAVPRL,AII,AII/AVP,AVP,Angiotensin/vasopressin receptor AII/AVP-like,C1orf7,CIAS1,CLR1.1,Caterpiller protein 1.1 (CLR1.1),Cias1,Cold-induced autoinflammatory syndrome 1 protein,Cryopyrin,DFNA34,FCAS,FCAS1,FCU,KEFH,LRR and PYD domains-containing protein 3,MWS,Mmig1,NACHT,NALP3,NLRP3,Nlrp3,PYPAF1,PYRIN-containing APAF1-like protein 1,Pypaf1

Target products collectionGo to NLRP3 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No. Product Name Species Reactivity
GM-Tg-hg-T08499-Ag-1/ GM-Tg-hg-T08499-Ag-2 Human NLRP3 protein Human
GM-Tg-rg-T08499-Ag-1/ GM-Tg-rg-T08499-Ag-2 Rat NLRP3 protein Rat
GM-Tg-mg-T08499-Ag-1/ GM-Tg-mg-T08499-Ag-2 Mouse NLRP3 protein Mouse
GM-Tg-cynog-T08499-Ag-1/ GM-Tg-cynog-T08499-Ag-2 Cynomolgus/Rhesus macaque NLRP3 protein Cynomolgus/ Rhesus macaque
GM-Tg-felg-T08499-Ag-1/ GM-Tg-felg-T08499-Ag-2 Feline NLRP3 protein Feline
GM-Tg-cang-T08499-Ag-1/ GM-Tg-cang-T08499-Ag-2 Canine NLRP3 protein Canine
GM-Tg-bovg-T08499-Ag-1/ GM-Tg-bovg-T08499-Ag-2 Bovine NLRP3 protein Bovine
GM-Tg-equg-T08499-Ag-1/ GM-Tg-equg-T08499-Ag-2 Equine NLRP3 protein Equine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No. GM-Tg-hg-T08499-Ag-1/ GM-Tg-hg-T08499-Ag-2; GM-Tg-rg-T08499-Ag-1/ GM-Tg-rg-T08499-Ag-2;
GM-Tg-mg-T08499-Ag-1/ GM-Tg-mg-T08499-Ag-2; GM-Tg-cynog-T08499-Ag-1/ GM-Tg-cynog-T08499-Ag-2;
GM-Tg-felg-T08499-Ag-1/ GM-Tg-felg-T08499-Ag-2; GM-Tg-cang-T08499-Ag-1/ GM-Tg-cang-T08499-Ag-2;
GM-Tg-bovg-T08499-Ag-1/ GM-Tg-bovg-T08499-Ag-2; GM-Tg-equg-T08499-Ag-1/ GM-Tg-equg-T08499-Ag-2
Products Name NLRP3 protein
Species Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine
Target Name NLRP3
Protein Sub-location Secreted Protein/Potential Cytokines
Isotypes Recombinant protein
Expression platform Mammalian cell
Bioactivity validation Affintiy&bioactivity validated by ELISA, cell culture validated.
Tag His
Products description Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine NLRP3 protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Purity Purity: ≥95% (SDS-PAGE)
Application In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference






    About Gmab

    GDU
    GDU

    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.